Evidence evaluation of 12 commonly-used Chinese patent medicines in treatment of osteoporosis based on Eff-iEC and GRADE.
10.19540/j.cnki.cjcmm.20250427.501
- Author:
Guang-Cheng WEI
1
;
Zhi-Long ZHANG
1
;
Xin-Wen ZHANG
2
;
Ye LUO
3
;
Jin-Jie SHI
2
;
Rui MA
2
;
Jie-Yang DU
2
;
Ke ZHU
1
;
Jiu-Cheng PENG
2
;
Yu-Long YA
2
;
Wei CAO
1
Author Information
1. Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing 100102, China.
2. Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing 100102, China Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
3. Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicines;
Eff-iEC;
GRADE;
evidence;
osteoporosis
- MeSH:
Drugs, Chinese Herbal/therapeutic use*;
Osteoporosis/drug therapy*;
Humans;
Nonprescription Drugs/therapeutic use*;
Evidence-Based Medicine;
Medicine, Chinese Traditional
- From:
China Journal of Chinese Materia Medica
2025;50(15):4372-4385
- CountryChina
- Language:Chinese
-
Abstract:
This study applied the grading of recommendations assessment, development and evaluation(GRADE) system and the integrated evidence chain-based effectiveness evaluation of traditional Chinese medicine(Eff-iEC) to evaluate the evidence for 12 commonly used Chinese patent medicines for the treatment of osteoporosis, which are frequently recommended in guidelines or expert consensuses. The results showed that Xianling Gubao Capsules/Tablets were rated as C(low-level evidence) according to the GRADE system, and as BA~+B~+(intermediate evidence) according to the Eff-iEC system. Jintiange Capsules were rated as C(low-level evidence) by the GRADE system, and as AA~+B(high-level evidence) by the Eff-iEC system. Gushukang Granules/Capsules were rated as C(low-level evidence) by GRADE system, and as BA~+B~+(intermediate evidence) by Eff-iEC system. Zuogui Pills were rated as C(low-level evidence) by GRADE system, and as AA~(++)B~+(high-level evidence) by Eff-iEC system. Qianggu Capsules were rated as D(extremely low-level evidence) by GRADE system, and as AA~+B~+(high-level evidence) by Eff-iEC system. Zhuanggu Zhitong Capsules were rated as D(extremely low-level evidence) by GRADE system, and as BA~+B(intermediate evidence) by Eff-iEC system. Jingui Shenqi Pills were rated as D(extremely low-level evidence) by GRADE system, and as AA~+B(high-level evidence) by Eff-iEC system. Quanduzhong Capsules were rated as D(extremely low-level evidence) by GRADE system, and as AD~+B~+(low-level evidence) by Eff-iEC system. Epimedium Total Flavones Capsules were rated as D(extremely low-level evidence) by GRADE system, and as AAB~+(high-level evidence) by Eff-iEC system. Yougui Pills were rated as D(extremely low-level evidence) by GRADE system, and as AA~(++)B~(+ )(high-level evidence) by Eff-iEC system. Qigu Capsules were rated as D(extremely low-level evidence) by GRADE system, and as BB~+B(intermediate evidence) by Eff-iEC system. Liuwei Dihuang Pills were rated as C(low-level evidence) by GRADE system, and as AA~(++)B~+(high-level evidence) by Eff-iEC system. Overall, the Eff-iEC system provides a more comprehensive assessment of the effectiveness evidence for traditional Chinese medicine(TCM) than the GRADE system. However, it still has certain limitations that hinder its wider promotion and application. In terms of clinical evidence evaluation, both the Eff-iEC and GRADE systems reflect that the current clinical research quality on Chinese patent medicines for the treatment of osteoporosis is generally low. High-quality clinical trials are still needed in the future to further validate clinical efficacy.
